Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509417 | 0.97 | DRD2 (0.45) | DRD2MCHR1DRD3DRD4HTR1A | |
| SCHEMBL5515430 | 0.97 | DRD2 (0.46) | DRD2MCHR1DRD3DRD4HTR1A | |
| SCHEMBL5511457 | 0.96 | DRD2 (0.46) | DRD2MCHR1DRD3DRD4HTR1A | |
| SCHEMBL5509918 | 0.89 | KCNH2 (0.46) | DRD2MCHR1DRD4HTR1AKCNH2 | |
| SCHEMBL5517092 | 0.88 | KCNH2 (0.47) | DRD2MCHR1DRD4HTR1AKCNH2 | |
| SCHEMBL5522239 | 0.85 | ADRA1D (0.58) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5515023 | 0.85 | ADRA1D (0.49) | DRD2MCHR1DRD4ADRA1DADRA1A | |
| SCHEMBL5511409 | 0.83 | DRD2 (0.48) | DRD2MCHR1DRD4HTR1AKCNH2 | |
| SCHEMBL5511501 | 0.83 | DRD2 (0.67) | DRD2MCHR1ADRA1A | |
| SCHEMBL5511369 | 0.80 | DRD2 (0.65) | DRD2MCHR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7105544-B2 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2006-02-23 | — | — | US | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| US-20040073036-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073036-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885DRD3 103/4885 |
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885DRD3 103/4885 |
| US-20060041139-A9 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885DRD3 103/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | DRD2 74/4885MCHR1 1/4885DRD3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.